Crotamine toxicity and efficacy in mouse models of melanoma

Expert Opinion on Investigational Drugs

Volumn 20, Issue 9, 2011, Pages 1189-1200

  Pereira, Alexandre ^a   Kerkis, Alexandre ^b   Hayashi, Mirian Af ^d   Pereira, Aparecida Sp ^c   Silva, Fernando S ^a   Oliveira, Eduardo B ^e   Prieto Da Silva, Alvaro Rb ^a   Yamane, Tetsuo ^f   Rádis Baptista, Gandhi ^g   Kerkis, Irina ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b Celltrovet   (Brazil)

^c Laboratory of Virology   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f State University of Amazon   (Brazil)

^g FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Antimicrobial peptides; Cancer cells selective toxicity; Cell penetrating peptides; Chemotherapeutical compound; Tumor growth arrest

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; CROTAMINE; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STAGING; CANCER TRANSPLANTATION; CELL VIABILITY; CLINICAL EVALUATION; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; KAPLAN MEIER METHOD; LIFE EXTENSION; LIFESPAN; MEDICAL RECORD; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CROTALID VENOMS; DISEASE MODELS, ANIMAL; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SKIN NEOPLASMS;

EID: 80051777104     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.602064     Document Type: Article

References (40)

1. Radis-Baptista G, Oguiura N, Hayashi MA, et al. Nucleotide sequence of crotamine isoform precursors from a single South American rattlesnake (Crotalus durissus terrificus). Toxicon 1999;37:973-84 (Pubitemid 29234088)
2. Radis-Baptista G, de la Torre T, Andreu D. A novel cell-penetrating peptide sequence derived by structural minimization of a snake toxin exhibits preferential nucleolar localization. J Med Chem 2008;51:7041-4
3. Chang CC, Tseng KH. Effect of crotamine, a toxin of South American rattlesnake venom, on the sodium channel of murine skeletal muscle. Br J Pharmacol 1978;63:551-9 (Pubitemid 8373738)
4. Ownby CL, Aird S, Kaiser II. Physiological and immunological properties of small myotoxins from the venom of the midget faded rattlesnake (Crotalus viridis concolor). Toxicon 1988;20:319-23
5. Kerkis A, Kerkis I, Radis-Baptista G, et al. Crotamine is a novel cell-penetrating protein from the venom of rattlesnake Crotalus durissus terrificus. FASEB J 2004;18:1407-9 (Pubitemid 39561596)
6. Kerkis A, Hayashi MA, Yamane T, Kerkis I. Properties of cell-penetrating peptides (CPPSs). IUBMB Life 2006;58:7-13
7. Nascimento FD, Hayashi MA, Kerkis A, et al. Crotamine mediates gene delivery into cells through the binding to heparan sulfate proteoglycans. J Biol Chem 2007;282:21349-60 (Pubitemid 47099945)
8. Hayashi MA, Nascimento FD, Kerkis A, et al. Cytotoxic effects of crotamine are mediated through lysosomal membrane permeabilization. Toxicon 2008;52:508-17
9. Yount NY, Kupferwasser D, Spisni A, et al. Selective reciprocity in antimicrobial activity versus cytotoxicity of hBD-2 and crotamine. Proc Natl Acad Sci USA 2009;106:14972-7
10. Nicastro G, Franzoni L, de Chiara C, et al. Solution structure of crotamine, a Na+ channel affecting toxin from Crotalus durissus terrificus venom. Eur J Biochem 2003;270:1969-79 (Pubitemid 36560818)
11. Fadel V, Bettendorff P, Herrmann T, et al. Automated NMR structure determination and disulfide bond identification of the myotoxin crotamine from Crotalus durissus terrificus. Toxicon 2005;46:759-67 (Pubitemid 41531602)
12. Easton DM, Nijnik A, Mayer ML, Hancock RE. Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol 2009;27:582-90
13. Joanne P, Nicolas P, El Amri C. Antimicrobial peptides and viral fusion peptides: how different they are? Protein Pept Lett 2009;16:743-50
14. Nicolas P, Rosenstein Y. Multifunctional host defense peptides. FEBS J 2009;276:6464
15. Auvynet C, Rosenstein Y. Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in innate and adaptive immunity. FEBS J 2009;276:6497-508
16. Pieters RJ, Arnusch CJ, Breukink E. Membrane permeabilization by multivalent anti-microbial peptides. Protein Pept Lett 2009;16:736-42
17. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 2006;19:491-511 (Pubitemid 44137212)
18. Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol 2009;625:190-4
19. Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 2008;1778:357-75
20. Sitaram N, Nagaraj R. The therapeutic potential of host-defense antimicrobial peptides. Curr Drug Targets 2002;3:259-67 (Pubitemid 34555498)
21. Radis-Baptista G, Kerkis A, Prieto-Silva RA, et al. Membrane- translocating peptides and toxins: from nature to bedside. J Braz Chem Soc 2008;19:211-25
22. Nekhotiaeva N, Elmquist A, Rajarao GK, et al. Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. FASEB J 2004;18(2):394-6
23. Henriques ST, Melo MN, Castanho MA. Cell-penetrating peptides and antimicrobial peptides: how different are they? Biochem J 2006;399:1-7 (Pubitemid 44505401)
24. Foerg C, Merkle HP. On the biomedical promise of cell-penetrating peptides: limits versus prospects. J Pharm Sci 2008;97:144-62
25. Nicolas P. Multifunctional host defense peptides: intracellular-targeting antimicrobial peptides. FEBS J 2009;276:6483-96
26. Harada H, Kizaka-Kondoh S, Hiraoka M. Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer 2006;13:16-26
27. Taylor BN, Mehta RR, Yamada T, et al. Noncationic peptides obtained from Azurin preferentially enter cancer cells. Cancer Res 2009;69:537-46
28. Oguiura N, Camargo ME, da Silva ARP, Horton DS. Quantification of crotamine, a small basic myotoxin, in South American rattlesnake (Crotalus durissus terrificus) venom by enzyme-linked immunosorbent assay with parallel-lines analysis. Toxicon 2000;38:443-8 (Pubitemid 29531583)
29. Fehrenbacher N, Jaattela M. Lysosomes as targets for cancer therapy. Cancer Res 2005;65:2993-5 (Pubitemid 40524572)
30. Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 2008;27:6434-51
31. Almeida PF, Pokorny A. Mechanisms of antimicrobial, cytolytic, and cell-penetrating peptides: from kinetics to thermodynamics. Biochemistry 2009;48:8083-93
32. Zhu WL, Hahm KS, Shin SY. Cell selectivity and mechanism of action of short antimicrobial peptides designed from the cell-penetrating peptide Pep-1. J Pept Sci 2009;15:569-75
33. Oguiura N, Boni-Mitake M, Radis-Baptista G. New view on crotamine, a small basic polypeptide myotoxin from South American rattlesnake venom. Toxicon 2005;46:363-70 (Pubitemid 41218730)
34. Pazgier M, Hoover DM, Yang D, et al. Human beta-defensins. Cell Mol Life Sci 2006;63:1294-313
35. Sanderson RD. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 2001;12:89-98
36. Hannon MJ. Supramolecular DNA recognition. Chem Soc Rev 2007;36:280-95
37. Ashwell S, Zabludoff S. DNA damage detection and repair pathways-recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008;14:4032-7
38. Kochi SK, Collier RJ. DNA fragmentation and cytolisis in U937 cells treated with Diphteria toxin or other inhibitors of protein synthesis. Exp Cell Res 1993;208:296-302 (Pubitemid 23274516)
39. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000;256:12-18 (Pubitemid 30211161)
40. Lee J-Y, Choi Y-S, Suh J-S, et al. Cell-penetrating chitosan/doxorubicin/ TAT conjugates for efficient cancer therapy. Int J Cancer 2011;128:2470-80